Skip to content

Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects

Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01923519
Acronym
GENEBRO
Enrollment
44
Registered
2013-08-15
Start date
2013-11-29
Completion date
2017-05-07
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

The respiratory epithelium plays a leading role in the development of allergic respiratory disease with barrier function alteration, its repair mechanisms, of anti-viral fight and the ability to induce by itself Th2 responses. The majority of allergic asthmatic patients have reached concomitant ENT: the concept of "one airway, one disease." Access to this material of epithelial study in the different phenotypes of the disease appears to be crucial. Nasal and bronchial epithelial tissues reveal essential differences in particular related to their environment (remodeling less intense and a lower sensitivity to the virus in the nose), but they nevertheless share many common cellular characteristics.

Interventions

PROCEDUREbronchofiberscopy

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* age ≥ 18 years and \<30 years * isolated allergic rhinitis according to clinical criteria ARIA * absence of asthma whose diagnosis is made based on clinical criteria or mild to moderate persistent asthma controlled with a diagnosis is made based on clinical criteria

Exclusion criteria

* recent rhino-bronchial infection (\<6 weeks) * asthma exacerbation in the previous 6 weeks * Chronic disease may in the opinion of the investigators interfere with the results of the study or expose them to additional risk. * Treatment with nasal corticosteroids, inhaled or systemic in the past 6 weeks * Current smoking no history of smoking or not smoking for at least 12 months and weaned smoking history \<5 pack-years) * Special Needs

Design outcomes

Primary

MeasureTime frame
genic expression profile of the epithelium3 months after inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026